Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference9 articles.
1. Lee S, Zhou J, Leung KSK, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07319-x
2. Zhou J, Lee S, Leung KSK, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Fail. 2022;9(2):1388–99.
3. Siasos G, Bletsa E, Stampouloglou PK, et al. Novel antidiabetic agents: cardiovascular and safety outcomes. Curr Pharm Des. 2020;26(46):5911–32.
4. Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10(10):CD013650.
5. Cotter G, Davison BA, Edwards C, et al. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. Am Heart J. 2021;240:73–80.